Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 26 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue SarcomaTerminatedNCT03711279Phase 2Results posted
• Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerCompletedNCT03704688Phase 1/2Results posted
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• Topical Ruxolitinib Lichen PlanusCompletedNCT03697460Phase 2Results posted
• Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingNCT03697408Phase 1/2Results posted
• A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) StudyTerminatedNCT03693625Phase 2Results posted
• A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted TherapyActive, not recruitingNCT03690388Phase 3Results posted
• Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTTerminatedNCT03689894Phase 1/2Results posted
• Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
• Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand EczemaCompletedNCT03683719Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisCompletedNCT03682705Phase 2Results posted
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell CarcinomaCompletedNCT03680521Phase 2Results posted
• Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's MacroglobulinemiaTerminatedNCT03679624Phase 2Results posted
• A Study to Test Whether Nintedanib Influences the Components of Birth-control Pills in Women With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)CompletedNCT03675581Phase 1Results posted
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.CompletedNCT03675477Phase 2Results posted
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibActive, not recruitingNCT03673501Phase 3Results posted
• Long Term Safety Observation of Crizotinib in Chinese NSCLC PopulationTerminatedNCT03672643Phase 4Results posted
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT03666143Phase 1Results posted
• Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue SarcomasTerminatedNCT03660930Phase 1/2Results posted
• Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingNCT03660826Phase 2Results posted
• A Renal Impairment Study for PF-04965842CompletedNCT03660241Phase 1Results posted
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal CancerActive, not recruitingNCT03657641Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaTerminatedNCT03656536Phase 3Results posted
• PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706TerminatedNCT03655236Phase 2Results posted
• Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedNCT03654833Phase 2Results posted
• Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid LeukemiaActive, not recruitingNCT03654768Phase 2Results posted
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic DermatitisTerminatedNCT03654755Phase 2Results posted
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03653026Phase 3Results posted
• Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic CancerTerminatedNCT03649321Phase 1/2Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• Sunitinib in Sarcomas of the Central Nervous SystemTerminatedNCT03641326Phase 2Results posted
• Efficacy and Safety of TD-1473 in Crohn's DiseaseTerminatedNCT03635112Phase 2Results posted
• Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results posted
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 3Results posted
• A Hepatic Impairment Study for PF-04965842.CompletedNCT03626415Phase 1Results posted
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedNCT03624127Phase 3Results posted
• Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
• A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)CompletedNCT03616964Phase 3Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusTerminatedNCT03616912Phase 3Results posted
• Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic GlucocorticoidsCompletedNCT03616184Phase 2Results posted
• An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03611751Phase 3Results posted
• Lenvatinib and Pembrolizumab Simultaneous Combination StudyCompletedNCT03609359Phase 2Results posted
• A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03607487Phase 2Results posted
• A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)CompletedNCT03607422Phase 3Results posted
• A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT03601897Phase 1/2Results posted
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTerminatedNCT03599622Phase 2Results posted
• DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerTerminatedNCT03599518Phase 1Results posted
• Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsActive, not recruitingNCT03598244Phase 1Results posted
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung CancerCompletedNCT03596866Phase 3Results posted
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)Active, not recruitingNCT03595124Phase 2Results posted
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal CancerTerminatedNCT03592641Phase 2Results posted
• A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT03589326Phase 3Results posted
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular CarcinomaCompletedNCT03586973Phase 2Results posted
• A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedNCT03585296Phase 2Results posted
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedNCT03584516Phase 2/3Results posted
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic TumorsCompletedNCT03583086Phase 1/2Results posted
• Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLLActive, not recruitingNCT03580928Phase 2Results posted
• (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisCompletedNCT03580655Phase 2Results posted
• Tofacitinib for Inflammatory Eye DiseaseStatus unknownNCT03580343Phase 2Results posted
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03575871Phase 3Results posted
• Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLLTerminatedNCT03572634Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia AreataCompletedNCT03570749Phase 2/3Results posted
• A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03569371Phase 2Results posted
• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)CompletedNCT03569293Phase 3Results posted
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisActive, not recruitingNCT03568318Phase 3Results posted
• Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT03562507Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT03559270Phase 3Results posted
• JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT03557970Phase 2Results posted
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedNCT03555149Phase 1/2Results posted
• Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)TerminatedNCT03552029Phase 1Results posted
• Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedNCT03551821Phase 2Results posted
• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1Results posted
• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal CancerCompletedNCT03542877Phase 2Results posted
• Lorlatinib Renal Impairment StudyCompletedNCT03542305Phase 1Results posted
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibCompletedNCT03535740Phase 2Results posted
• Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results posted
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)CompletedNCT03531957Phase 2Results posted
• Effect of a Proton Pump Inhibitor on the PK of TepotinibCompletedNCT03531762Phase 1Results posted
• Lenvatinib and Eribulin in Advanced Soft Tissue SarcomaCompletedNCT03526679Phase 1/2Results posted
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)Active, not recruitingNCT03521154Phase 3Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung CancerCompletedNCT03520842Phase 2Results posted
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted
• Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaTerminatedNCT03514017Phase 2Results posted
• BGJ398 for the Treatment of Tumor-Induced OsteomalaciaTerminatedNCT03510455Phase 2Results posted
• Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT03506373Phase 2Results posted
• Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid CancerTerminatedNCT03506048Phase 2Results posted
• Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)CompletedNCT03502616Phase 3Results posted
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedNCT03495817Phase 2Results posted
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionCompletedNCT03494816Phase 2Results posted
• Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host DiseaseCompletedNCT03491215Phase 1/2Results posted
• Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisCompletedNCT03486457Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK and Evaluation of Relative Bioavailability of TAK-788 Capsules in Healthy ParticipantsCompletedNCT03482453Phase 1Results posted
• Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib TrialsCompletedNCT03477175Phase 2Results posted
• A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03474679Phase 3Results posted
• Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaCompletedNCT03473756Phase 1Results posted

← Tyrosine Kinase Inhibitors overview